相似文献
1
Torcetrapib and coronary events.
N Engl J Med. 2008 Apr 24;358(17):1862-3; author reply 1863-4. doi: 10.1056/NEJMc073441.
2
Torcetrapib and coronary events.
N Engl J Med. 2008 Apr 24;358(17):1863; author reply 1863-4.
3
Is a blood pressure rise the only deleterious off-target effect of cholesterol ester transfer protein inhibitors?
J Hypertens. 2010 Aug;28(8):1614-6. doi: 10.1097/HJH.0b013e32833c575b.
4
Torcetrapib and coronary events.
N Engl J Med. 2008 Apr 24;358(17):1863; author reply 1863-4.
5
The failure of torcetrapib: was it the molecule or the mechanism?
Arterioscler Thromb Vasc Biol. 2007 Feb;27(2):257-60. doi: 10.1161/01.ATV.0000256728.60226.77.
6
Torcetrapib: when global risk reduction goes 'off target'.
Int J Clin Pract. 2008 Feb;62(2):173-4. doi: 10.1111/j.1742-1241.2007.01687.x.
7
Cholesteryl ester transfer protein (CETP) inhibitors: is there life after torcetrapib?
Cardiol Clin. 2008 Nov;26(4):537-46. doi: 10.1016/j.ccl.2008.06.005.
8
Illuminating HDL--is it still a viable therapeutic target?
N Engl J Med. 2007 Nov 22;357(21):2180-3. doi: 10.1056/NEJMe0707210. Epub 2007 Nov 5.
9
Spotlight on HDL-raising therapies: insights from the torcetrapib trials.
Nat Clin Pract Cardiovasc Med. 2008 Jun;5(6):329-36. doi: 10.1038/ncpcardio1191. Epub 2008 Apr 22.
10
Torcetrapib produces endothelial dysfunction independent of cholesteryl ester transfer protein inhibition.
J Cardiovasc Pharmacol. 2010 May;55(5):459-68. doi: 10.1097/FJC.0b013e3181cf03cb.
Zotero 插件